Unlocking the money-making potential of RNAi

Nature Biotechnology

Volumn 21, Issue 12, 2003, Pages 1441-1446

  Howard, Ken ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

RNA;

BIOTECHNOLOGY; DRUG MARKETING; FINANCIAL MANAGEMENT; FOOD AND DRUG ADMINISTRATION; GENE ACTIVITY; GENE IDENTIFICATION; INVESTMENT; MOLECULAR BIOLOGY; PRIORITY JOURNAL; REVIEW; TECHNOLOGY;

BIOTECHNOLOGY; DRUG INDUSTRY; GENE THERAPY; GENETIC ENGINEERING; OWNERSHIP; PATENTS; RNA INTERFERENCE;

EID: 0348014778     PISSN: 10870156     EISSN: None     Source Type: Journal    
DOI: 10.1038/nbt1203-1441     Document Type: Review

References (2)

1. Front Line Strategic Consulting. siRNA: A Strategic Market Outlook and Business Analysis (Front Line Strategic Consulting, San Mateo, CA, USA, February 2003).
2. McCaffrey, A.P. et al. Inhibition of hepatitis B virus in mice by RNA interference. Nat. Biotechnol. 21, 639-644 (2003).